<?xml version="1.0" encoding="UTF-8"?>
<ref id="B35-molecules-26-01107">
 <label>35.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Villa</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Thellung</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Bajetto</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Gatta</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Robello</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Novelli</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Tasso</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Tonelli</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Florio</surname>
    <given-names>T.</given-names>
   </name>
  </person-group>
  <article-title>Novel celecoxib analogues inhibit glial production of prostaglandin E2, nitric oxide, and oxygen radicals reverting the neuroinflammatory responses induced by misfolded prion protein fragment 90â€“231 or lipopolysaccharide</article-title>
  <source>Pharm. Res.</source>
  <year>2016</year>
  <volume>113</volume>
  <fpage>500</fpage>
  <lpage>514</lpage>
  <pub-id pub-id-type="doi">10.1016/j.phrs.2016.09.010</pub-id>
  <?supplied-pmid 27667770?>
  <pub-id pub-id-type="pmid">27667770</pub-id>
 </element-citation>
</ref>
